Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIFKUX)

• Drug Name: [3H]CNQX Drug Info
• Synonyms: 6-Cyano-7-nitroquinoxaline-2,3-dione; CNQX; 115066-14-3; 6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; 7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile; UNII-6OTE87SCCW; FG 9065; 6OTE87SCCW; FG-9065; 6-Cyano-2,3-dihydroxy-7-nitroquinoxaline; CHEBI:34468; 1,4-dihydro-2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile; 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-; ST50405216; 2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; FG9065; AC1MWAKF; Tocris-0190; Biomol-NT_000200; 6-cyano-7-nitroquinoxaline-2,3-dione

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3721046
  ChEBI ID: CHEBI:34468
  CAS Number: CAS 115066-14-3
  TTD Drug ID: DMIFKUX

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor AMPA 1 (GRIA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[7]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[8]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[9]
Farampator	DM76GRQ	Major depressive disorder	6A70.3	Discontinued in Phase 1	[10]
GYKI-52466	DM3YG5P	Alzheimer disease	8A20	Terminated	[11]
GYKI-53655	DMC0JN8	N. A.	N. A.	Terminated	[12]
Zonampanel	DM70HZD	N. A.	N. A.	Terminated	[9]
SORETOLIDE	DMTDLHG	Convulsion	8A68.Z	Terminated	[13]
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[14]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Glutamate receptor AMPA 2 (GRIA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[7]
Paliroden	DMX8ZAQ	Parkinson disease	8A00.0	Phase 2	[16]
ATPO	DMXLS78	Discovery agent	N.A.	Investigative	[4]
(S)-5-fluorowillardiine	DMCIZ7P	Discovery agent	N.A.	Investigative	[4]
[3H]AMPA	DMLF7SG	N. A.	N. A.	Investigative	[4]

Drug(s) Targeting Glutamate receptor AMPA (GRIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[17]
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[18]
Zopiclone	DMPI6Z0	Insomnia	7A00-7A0Z	Approved	[19]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[20]
Enflurane	DM0YJSB	Anaesthesia	9A78.6	Approved	[21]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[22]
Bromazepam	DMY9TCW	Anxiety disorder	6B00-6B0Z	Approved	[23]
Artemisinin SP	DMFETDK	Malaria	1F40-1F45	Approved	[24]
Dihydroergotoxine	DM5D6WZ	Alzheimer disease	8A20	Approved	[25]
Barbiturate	DMJIA6T	Anaesthesia	9A78.6	Approved	[26]

Drug(s) Targeting Glutamate receptor AMPA 3 (GRIA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[7]
ATPO	DMXLS78	Discovery agent	N.A.	Investigative	[5]
(S)-5-fluorowillardiine	DMCIZ7P	Discovery agent	N.A.	Investigative	[5]
[3H]AMPA	DMLF7SG	N. A.	N. A.	Investigative	[5]
joro toxin	DMYBJ4K	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Glutamate receptor AMPA 4 (GRIA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[7]
ATPO	DMXLS78	Discovery agent	N.A.	Investigative	[6]
(S)-5-fluorowillardiine	DMCIZ7P	Discovery agent	N.A.	Investigative	[6]
[3H]AMPA	DMLF7SG	N. A.	N. A.	Investigative	[6]
joro toxin	DMYBJ4K	Discovery agent	N.A.	Investigative	[6]
AMG-889436	DMKP8L9	Parkinson disease	8A00.0	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Inhibitor	[2]
Glutamate receptor AMPA 1 (GRIA1)	TTVPQTF	GRIA1_HUMAN	Antagonist	[3]
Glutamate receptor AMPA 2 (GRIA2)	TT9HLZ0	GRIA2_HUMAN	Antagonist	[4]
Glutamate receptor AMPA 3 (GRIA3)	TT82EZV	GRIA3_HUMAN	Modulator	[5]
Glutamate receptor AMPA 4 (GRIA4)	TTPJR0G	GRIA4_HUMAN	Modulator	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4081).
• [2] Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. J Med Chem. 2006 Apr 20;49(8):2579-92.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
• [7] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [8] Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
• [9] Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
• [10] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [11] New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
• [12] Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
• [13] Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.
• [14] 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
• [15] Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
• [16] Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44.
• [17] Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
• [18] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [19] Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
• [20] Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
• [21] Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
• [22] Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
• [23] Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
• [24] GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
• [25] Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
• [26] Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.